



ජාතික මානද තියාමන අධිකාරිය  
තොසිය මරුන්තුකள් ඉහුණුප්‍රාග්ධන අනිකාර සංඝ  
National Medicines Regulatory Authority

ඡායා අංකය  
නො. තිය.  
My No.

NMRA/PV/AWP/2025-01

ඡායා අංකය  
නො. තිය.  
Your No.

දිනය  
තියුණ  
Date

02.09.2025

Directors,  
National/Teaching Hospitals – Sri Lanka

**Subject: Invitation to Register the Virtual Awareness Program to Enhance Adverse Drug Reaction (ADR) Reporting.**

Dear sir/madam,

The National Medicines Regulatory Authority-Sri Lanka, through its Pharmacovigilance Division; is fundamentally committed to safeguarding public health by establishing a robust system for the continuous monitoring of drugs, a process in which the reporting of Adverse Drug Reactions (ADRs) plays an indispensable role.

Timely and accurate ADR reporting is not merely a regulatory requirement; it is a critical practice that allows us to identify potential risks and take necessary action to protect patients.

To strengthen this vital function within government hospitals, we have organized a comprehensive **virtual awareness program on 30<sup>th</sup> September 2025 at 10.00 AM**. This initiative is designed to equip your key staff members with the knowledge and standardized protocols necessary to contribute to a more efficient and reliable national drug safety monitoring network.

We kindly request **formal registration of relevant personnel** from your institution, including clinicians, pharmacists, and nurses, **on or before 27<sup>th</sup> September 2025** via the below registration link.

**Registration Link:** <https://forms.gle/HY4nHeF74vQS1kQ36>

Contact for Inquiries: pa3@nmra.gov.lk

Thank you

**Dr. K.M.G.K. Bandara**

MBBS, MSc, MD (Com. Med), MA (Sociology)

Chief Executive Officer (Acting)

National Medicines Regulatory Authority

130, W.A.D Ramanayake Mawatha, Colombo 02.

  
Dr. K. M. G. K. Bandara.

Chief Executive Officer

National Medicines Regulatory Authority.



+94 11 269 51 73 | +94 11 269 88 96/7



+94 11 252 33 85



www.nmra.gov.lk



info@nmra.gov.lk